A313

Gwyneth Paltrow may deserve partial credit for the whole phenomenon. When she praised the old French ointment Avibon on Goop around 2012, she kicked off an American hunger for a cult vitamin-A cream sold cheaply in Paris pharmacies, an appetite that outlived the product that started it. Avibon itself was discontinued after batches were recalled in March 2013 over stability problems its maker Sanofi couldn't resolve to modern quality standards.

Into that vacuum stepped a near-identical replacement that quietly appeared the same year. The reformulation was not just a relabeling. The discontinued ointment had packed roughly a million IU of vitamin A into a fragranced lanolin base, while the successor carries 200,000 IU of retinyl palmitate suspended in a polyethylene-glycol (macrogol) base. That base swap matters: macrogol acts as both a stabilizer, addressing the very problem that sank its predecessor, and a penetration enhancer, which is a large part of why devotees insist the newer version actually performs.

The rise from there was almost entirely bottom-up. With no real advertising and a manufacturer, based in the small Burgundy town of Corbigny, that does little brand-building, the pommade spread by tourists smuggling tubes home in their luggage and by social media evangelists rebranding it as "affordable French retinol." That word-of-mouth status is essentially its entire identity, since it remains a one-product label rather than a developed skincare range.

More recently the formula was given a smoother texture and refreshed packaging, a modest update to a famously utilitarian tube. The honest assessment is unchanged by the makeover: this is pharmaceutical-grade vitamin A at a drugstore price, credible because of its pharmacy pedigree and stable base rather than any clinical-trial program on the finished product, and best approached as a potent, no-frills retinoid rather than a curated regimen.

Sources:[1][2][3]